ProSomnus (NASDAQ:OSA) versus Acutus Medical (NASDAQ:AFIB) Head-To-Head Review

Acutus Medical (NASDAQ:AFIBGet Free Report) and ProSomnus (NASDAQ:OSAGet Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Insider and Institutional Ownership

31.3% of Acutus Medical shares are owned by institutional investors. Comparatively, 7.9% of ProSomnus shares are owned by institutional investors. 3.5% of Acutus Medical shares are owned by insiders. Comparatively, 8.5% of ProSomnus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Acutus Medical and ProSomnus’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acutus Medical $16.36 million 1.09 -$39.62 million ($1.51) -0.40
ProSomnus $19.39 million 0.91 -$7.14 million N/A N/A

ProSomnus has higher revenue and earnings than Acutus Medical.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Acutus Medical and ProSomnus, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acutus Medical 0 0 0 0 N/A
ProSomnus 0 0 2 0 3.00

ProSomnus has a consensus price target of $10.00, suggesting a potential upside of 809.09%. Given ProSomnus’ higher probable upside, analysts clearly believe ProSomnus is more favorable than Acutus Medical.


This table compares Acutus Medical and ProSomnus’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acutus Medical -221.30% -67.47% -34.44%
ProSomnus N/A N/A -48.65%

Volatility and Risk

Acutus Medical has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, ProSomnus has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.


ProSomnus beats Acutus Medical on 7 of the 11 factors compared between the two stocks.

About Acutus Medical

(Get Free Report)

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.

About ProSomnus

(Get Free Report)

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolarygologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.

Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with's FREE daily email newsletter.